跳至主要内容
临床试验/NCT04542668
NCT04542668已完成不适用

An Open-label, Randomized, Cross-over Study to Investigate the Effect of Weight-bearing vs Non-weight-bearing Exercise and Cardiovascular Stress Without Load on Collagen and Proteoglycan in Serum and Urine in Patients With Osteoarthritis

Nordic Bioscience A/S2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年10月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Acute chances in biomarkers

研究概览

简要总结

The aim of EFEX-OA-02 is to explore how running, cycling, exercise simulation and resting acutely influence collagen and proteoglycan homeostasis in OA, as reflected by changes in collagen and proteoglycan levels in urine and serum.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cumulated Osteoarthritis Kellgren-Lawrence radiological grade of at least 2 in the tibio-femoral joints diagnosed by screening X-ray.
  • 40 to < 75 years of age at time of signing the informed consent.
  • Body weight > 50 and < 100 kg and BMI in the range 18.5-35 kg/m2 .
  • Male or female.
  • Able to attend all four study sessions and comply with the dietary and activity restrictions.
  • Able to provide informed consent

排除标准

  • Medical conditions:
  • Osteoarthritis Kellgren-Lawrence radiological grade of 4 in one or both knees.
  • Cumulated osteoarthritis Kellgren-Lawrence radiological grade no higher than
  • History of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening.
  • Previous arthroplasty of knee or hip.
  • Intention to have major surgery during the timeframe of the study.
  • Secondary OA related to e.g. any known trauma including cruciate ligament tears, meniscus tears and cartilage damage, dysplasia, aseptic osteonecrosis, acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout).
  • Current treatment with beta-receptor adrenergic antagonists (beta-blockers), MAO inhibitor, systemic corticosteroid treatment in doses equivalent to > 10 mg prednisolone per day, or vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated heparin.
  • Active systemic infection.
  • Active systemic inflammatory or autoimmune disease.
  • Any sign of previous or current cardiovascular disease.
  • Not currently an active athlete or highly trained individual.
  • Other exclusion criteria:
  • Legal incapacity or limited legal capacity.
  • Inability to communicate or cooperate with the investigator or to comply with the requirements of the entire study.
  • Categorized as being very difficult to draw blood from, as evaluated by the investigator.
  • Current alcohol abuse and/or inability to refrain from intake of alcoholic beverages for 24 hours prior to the study intervention.
  • Other factors, e.g. self-reported drug abuse, which in the opinion of the investigator may interfere with the performance of the study.
  • Site staff, study staff members and study staff family members.
  • Other concomitant disease compromising or otherwise significantly affecting ECM turnover in the opinion of the investigator.

结局指标

主要结局

Acute chances in biomarkers

时间窗: Acute: 0-4 hours and subacute: 24 hours

Serum and urine biochemical markers of joint related collagens and proteoglycan (not further specified)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验